Primrose Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Primrose Bio, Inc. - overview
Established
2023
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, Primrose Bio, Inc. operates as a biotechnology company that focuses on strain engineering and protein production for the development of therapeutics and vaccines for oncology and infectious diseases. Primrose Bio, Inc. was formed in 2023 by the merger of Pelican Technology Holdings (formerly Pfenex Inc.
) and Primordial Genetics, Inc. The firm as of July 2024, is led by its CEO, Helge Zieler. Primrose Bio’s flagship technology, Pfenex Expression Technology®, utilizes Pseudomonas fluorescens for efficient production of complex proteins, including antibodies and vaccine antigens. The Prima RNApols™ platform enhances mRNA production with high yield and quality, while the PeliCRM197® carrier protein is widely used in conjugate vaccines and therapeutics.
The company's product portfolio also includes commercialized offerings such as Rylaze®, developed through partnerships and approved by the FDA.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.primrosebio.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Primrose Bio, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.